Pacific Growth Downgrades Corixa to 'Neutral'
Analyst Tom Dietz cut his rating after the FDA called for additional clinical studies for the drug maker's cancer treatment
Pacific Growth downgraded Corixa (CRXA ) to neutral from buy.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like: